Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 2/20 | 0.32 |
| ▸ | MERTK | Q12866 | 2/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101576 | 1.00 | CSNK2A2 (0.34) | CSNK2A2CSNK2A1ACVRL1NTRK1AXL | |
| SCHEMBL10101582 | 0.92 | PIK3CD (0.34) | CSNK2A2CSNK2A1ACVRL1 | |
| SCHEMBL10101512 | 0.92 | PIK3CD (0.34) | CSNK2A2CSNK2A1ACVRL1 | |
| SCHEMBL13519789 | 0.89 | LGALS3 (0.35) | ACVRL1 | |
| SCHEMBL10101575 | 0.89 | CSNK2A2 (0.34) | CSNK2A2CSNK2A1ACVRL1NTRK1AXL | |
| SCHEMBL10101519 | 0.88 | NPC1 (0.36) | CSNK2A2CSNK2A1ACVRL1 | |
| SCHEMBL10101589 | 0.88 | NPC1 (0.36) | CSNK2A2CSNK2A1ACVRL1 | |
| SCHEMBL10101499 | 0.85 | ACVRL1 (0.38) | ACVRL1 | |
| SCHEMBL10101563 | 0.85 | ACVRL1 (0.38) | ACVRL1 | |
| SCHEMBL10101504 | 0.85 | PIK3CD (0.36) | ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119607-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-21 | — | — | US | disclosed |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | CSNK2A2 4716/4885CSNK2A1 4695/4885ACVRL1 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.